Back to top
more

IMab (IMAB)

(Delayed Data from NSDQ)

$1.80 USD

1.80
335,381

0.00 (0.00%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $1.80 0.00 (0.00%) 5:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for IMAB

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

I-Mab Sponsored ADR [IMAB]

Reports for Purchase

Showing records 1 - 20 ( 20 total )

Company: I-Mab Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 1

03/18/2024

Company Report

Pages: 7

Uliledlimab and Givastomig Look to Spearhead US Presence in Time

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: I-Mab Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 2

02/08/2024

Daily Note

Pages: 4

I-Mab’s US Renaissance is in Full Force with Divestment of China Operations and Assets; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: I-Mab Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 3

08/18/2023

Company Report

Pages: 8

A New Direction For I-Mab Starts to Take Shape, Though Patience is Required; Reit. Buy and Lowering Our PT to $18

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: I-Mab Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 4

04/03/2023

Company Report

Pages: 7

I-Mab’s Pipeline Refocusing Hopes to Alleviate Prior Headwinds

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: I-Mab Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 5

09/12/2022

Daily Note

Pages: 4

Lemzoparlimab ESMO Data Shines a Positive Light on Embattled CD47 Space; Reit. Buy and $45 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: I-Mab Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 6

08/31/2022

Company Report

Pages: 8

Reprioritized Core of Five Assets Looks to Pave a New Narrative; Reit. Buy and Lowering Our PT to $45

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: I-Mab Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 7

07/21/2022

Daily Note

Pages: 5

Reflective of Strong Fundamentals, I-Mab’s Pipeline Aims to Deliver Value Despite Volatile Market

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: I-Mab Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 8

06/10/2022

Daily Note

Pages: 5

Reflections of ASCO ‘22 - Part One: Cytokine Modalities Continue to Remain Overlooked

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: I-Mab Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 9

05/31/2022

Company Report

Pages: 7

Uliledlimab ASCO’ 22 Update Draws Mixed Sentiment; Reit. Buy and Lowering Our PT to $70 from $80

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: I-Mab Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 10

04/13/2022

Daily Note

Pages: 7

Conference Series Spotlight AACR 2022

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: I-Mab Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 11

03/30/2022

Company Report

Pages: 7

Overreaction to HFCAA Overhang Blinds True Upside Potential; Reit. Buy and Lowering Our PT to $80 from $95

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: I-Mab Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 12

02/14/2022

Daily Note

Pages: 6

Lessening ADR Risk Coupled to CD47 Landscape Dynamics Makes for an Attractive Entry Point

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: I-Mab Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 13

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for IMAB

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: I-Mab Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 14

09/01/2021

Company Report

Pages: 7

Pipeline Momentum Continues from All Angles; Reit Buy and Raising PT to $95

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: I-Mab Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 15

06/08/2021

Daily Note

Pages: 4

Uliliedlimab’s Displays Positive Efficacy Signals During ASCO 2021; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: I-Mab Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 16

04/27/2021

Daily Note

Pages: 7

I-Mab Hosts R&D Day, Highlighting Multiple Programs From an Expanding Pipeline

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: I-Mab Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 17

03/30/2021

Company Report

Pages: 7

Multiple Value Drivers Define 2021, Formidable Immuno-Oncology Pipeline Expands; Reit Buy and $75 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: I-Mab Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 18

03/03/2021

Company Report

Pages: 7

I-Mab’s Momentum Far From Terminal Velocity; Reit BUY and Raising PT to $75

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: I-Mab Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 19

12/07/2020

Company Report

Pages: 94

I-Mab, A Tale of Two Pillars; Initiate With a Buy and $55 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 150.00

Research Provided by a Third Party

Company: I-Mab Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 20

11/18/2020

Industry Report

Pages: 5

Reflections on SITC 2020 - Multifaceted Attacks Continue on Cancer.

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party